Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

109 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-26

Study Completion Date

2022-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical trial. The primary safety endpoint will be device-related adverse events. The primary effectiveness endpoint will be the improvement value of overactive bladder symptom score (OABSS) after 12-week treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.

NCT04483817

Overactive Bladder Syndrome

UNKNOWN NA

Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

NCT04113941

Overactive Bladder

UNKNOWN PHASE3

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

NCT05188742

Overactive Bladder Syndrome

UNKNOWN PHASE4

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

NCT00290563

Urinary Incontinence Overactive Bladder

COMPLETED PHASE2

Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol

NCT03559946

Overactive Bladder Syndrome

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Device: Non-invasive low-frequency tibial nerve stimulator

Group Type ACTIVE_COMPARATOR

Non-invasive low-frequency tibial nerve stimulator (TNS-01)

Intervention Type DEVICE

The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.

Sham

Device: Non-invasive low-frequency tibial nerve stimulator (same device operation without real current output)

Group Type SHAM_COMPARATOR

Non-invasive low-frequency tibial nerve stimulator (TNS-01)

Intervention Type DEVICE

The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-invasive low-frequency tibial nerve stimulator (TNS-01)

The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women and men aged between 18 and 80 years old (including 18 and 80 years old)；
2. Individual with primary OAB, or with OAB symptoms, satisfies one of the following conditions:

① Urinary urgency: sudden and strong desire to urinate, and it is difficult to be subjectively suppressed and delayed urination ;

② Urge urinary incontinence: accompanied with urinary urgency or immediately after urinary urgency ;

③ Urination frequency: adults urination frequency ≥8 times during the daytime，≥2 times at night, and each urine volume \<200 ml .
3. Individual meets the diagnostic criteria of OAB: According to the OABSS questionnaire, urgency score ≥2 points, total score ≥3 points, and symptoms duration ≥3 months;
4. Individual newly diagnosed with OAB have not been medicated, or is able to stop taking OAB-related drugs (M receptor block, β3 receptor agonists) for at least 2 weeks prior to enrollment;
5. The subject has autonomy and can go to the toilet independently;
6. Individual is ambulatory and able to use the toilet independently;
7. Individual is capable and willing to participate in the study and provide the written informed consent.

Exclusion Criteria

1. Woman is pregnant or lactating, or woman of childbearing age who plans to become pregnant during the study period;
2. Individual has Stress Urinary Incontinence (SUI);
3. Individual has obvious urinary obstruction due to various reasons accompanied by residual urine volume\> 100 ml;
4. Individual has an implanted pacemaker, embedded cardioverter defibrillator, or other electrical medical devices (including sacral neuromodulation (SNM) devices)
5. Individual has uncured urinary system infection;
6. Individual has urinary calculus resulting in lower urinary tract symptoms;
7. Individual has congenital urinary tract malformations causing uncured lower urinary tract symptoms;
8. Individual has uncured cancers;
9. Individual had undergone lower urinary tract surgery within 3 months;
10. Individual has neurological diseases or injuries accompanied with uncured lower urinary tract symptoms;
11. Individual has skin breakage, malignant tumor or acute purulent inflammation on the surface of the plantar where the electrode pads are to be placed;
12. Individual has participated in other drug clinical trials medical dev within 3 months, or participated in other ice clinical trials within 30 days;
13. Individual is deemed unsuitable for enrollment in the study by investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No